Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.
Hanneke Schuitemaker, PhD, Vice President and Head of Viral Vaccines Discovery and Translational Medicine at Janssen Vaccines, explains what makes Janssen’s new HIV-1 vaccine regimen unique.
Interview Transcript (slightly modified for readability):
“The vaccine differs from other regimens in that we are using low-seroprevalent adenoviral vectors that seem to really have a unique type of immunoresponse that they elicit. The antibodies that are being elicited by these vectors, in combination with the protein that we have in our regimen, seem to have really unique functionalities that are not being elicited by other vaccines. Whether this will be the unique feature that will give protection, or a higher level of protection, remains to be seen. We seem to have pretty good responses [so far] that make us optimistic.”